Amryt gets FDA orphan drug designation for Mycapssa for carcinoid syndrome
Amryt, a commercial-stage biopharma company, has secured orphan drug designation for Mycapssa (octreotide capsules) from the US Food and Drug Administration (FDA) for the treatment of carcinoid syndrome. Carcinoid syndrome is the most common functional syndrome related to neuroendocrine tumors (NETs) that affects less than 200,000 people in the US. Dr Joe Wiley — Amryt […]